Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05179447 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PROfiling Based Endometrial Cancer Adjuvant Therapy

Study acronym: PROBEAT
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2024 to Dec 31, 2026v5
  2. Primary completion date: Dec 31, 2023 to Dec 31, 2024
    • Study sites: 7 to 10
    • Study completion date: Jan 1, 2026 to Jan 1, 2027
    • Collaborators: 6 to 10
    v4
  3. Study title shortened, about 3 wordsv3
  4. Trial status: Not Yet Recruiting to Recruitingv2 Show 8 more changesShow less
    • Start date changed from estimate of Jan 1, 2022 to Jan 24, 2022
    • Secondary endpoints: details revised at 1 of 5 entries
    • Study description expanded, about 7 words
    • Site details revised at 7 of 7 sites
    • Collaborators expanded, about 27 words
    • Publications: 1 to 6
    • Study title revised
    • Eligibility criteria expanded, about 3 words
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, multicenter, randomized phase III trial among women with endometrioid adenocarcinoma with high-intermediate and intermediate risk features to investigate the role of integrated genomic-pathologic classification to determine if participants should receive no adjuvant therapy, vaginal brachytherapy, external beam radiotherapy or chemo-radiation therapy based on molecular features as compared to standard radiation therapy.
Trial Details
NCT Number NCT05179447
Lead Sponsor Women's Hospital School Of Medicine Zhejiang University
Collaborators: Tongji Hospital, Qilu Hospital of Shandong University, Obstetrics & Gynecology Hospital of Fudan University, Sun Yat-sen University, Peking University People's Hospital, Shanghai First Maternity and Infant Hospital, Xiangya Hospital of Central South University, Anhui Provincial Cancer Hospital, Ningbo Women & Children's Hospital, Ningbo No. 1 Hospital
Conditions
(from sponsor)		 Endometrial Cancer Stage I, Endometrial Cancer Stage II
Related terms Endometrial Neoplasms
Enrollment 590 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov